Felix Kim, PhD
Dr. Felix Kim is Co-founder and Head of Sigma1 Program. In addition, Felix currently serves as a Member of the Sidney Kimmel Cancer Center at Thomas Jefferson University, is an Assistant Professor at Drexel University, and is Secretary/Treasurer of the Translational and Clinical Pharmacology division of the American Society for Pharmacology and Experimental Therapeutics (ASPET). He is an expert in the pharmacology and biochemistry of Sigma1 in cancer. He has produced novel technologies and small molecule compounds used by scientists around the world to elucidate the role of Sigma1 in disease. Felix holds a BS in Biochemistry & Cell Biology from the University of California San Diego, a PhD in Biochemistry from Universitè Montpellier (France) for work performed at the Centre National de la Recherche Scientifique, and performed a post-doctoral fellowship in the Molecular Pharmacology & Chemistry Program at the Memorial Sloan Kettering Cancer Center.